Baltimore, MD (PRWEB) December 14, 2011
December 8th, 2011: SNBL-CPC one of the nation’s leading CRO dedicated to Phase I & IIa clinical research is pleased to announce new executive leadership with the arrival of Patrick R. Ayd as Chief Operating Officer (COO). As COO, Mr. Ayd will have overall responsibility managing SNBL-CPC’s clinical, administrative, and business development departments and optimizing the SNBL-CPC research platform to perform enhanced Phase I/IIa clinical trials of the highest quality for a wide variety of industry sponsors who require the utmost level of quality and white glove service when executing their Early Phase clinical trials.
Mr. Ayd was the former Vice President of Operations at SNBL-CPC. He managed the design and construction of the state of the art 96 bed Phase I facility which is located in the BioPark on the campus of the University of Maryland in Baltimore, MD. Mr. Ayd joins us from ClinPharm Network, Inc. where he served as the principal and founder of this small Early Phase operations and quality assurance consulting firm. He has held similar management & leadership positions in the clinical research industry including Omnicare Clinical Research, Biokenetic Clinical Applications, Bioanalytical Systems, Inc., and Parexel’s Clinical Research Unit in Baltimore. Mr. Ayd has over two decades of health care management experience, & his deep knowledge and experience in sourcing early phase clinical trials and managing Clinical Pharmacology Units will be of significant value to SNBL-CPC and all its customers who are seeking a strategic partner.
Takeshi “KC” Yamakawa CEO of SNBL-CPC stated, “It is fantastic to have Patrick back at SNBL. Patrick was a critical partner in establishing the SNBL unit in Baltimore. The infrastructure and operational foundation that he established 6 years ago assisted us in developing into a state of the art first in class inpatient clinical research facility. SNBL-CPC has always been a leader in the clinical research industry. Our growth is accelerating and it is critical to have a leader who can leverage our growth to build out our presence in the Early Phase inpatient clinical pharmacology arena and guide SNBL-CPC through multiple testing sectors such as adaptive design trials, special patient populations, infectious disease challenge trials, etc. The tradition of utilizing our capabilities to assist our client’s clinical development program will continue. Patrick was the obvious choice to manage our growth and continue the highest level of quality work that SNBL-CPC is known for in the Early Phase research industry.”
About SNBL Clinical Pharmacology Center:
SNBL-CPC is a 96 bed full service Clinical Pharmacology Research facility based in Baltimore, Maryland. Our team is focused on performing high complexity early phase clinical research programs. We conduct clinical trials for multiple segments of clients, including, pharmaceutical, biotech, academic, and government. In addition, SNBL-CPC offers all ancillary trial support services such as protocol consulting and design, data management, etc. for early phase I-IIa studies. SNBL’s focus is on First In-Human, Dose Escalation, SAD, MAD, Food Effect, Novel Delivery, Adaptive design, and Infectious Disease challenge studies sets us apart from the vast majority of Early Phase inpatient clinical research facilities. SNBL-CPC is pleased to offer our new, state of the art clinical safety laboratory that performs all of the standard safety analyses and moderate to high complexity test procedures.
For further information about SNBL-CPC or having our team mange your early phase clinical development program, please contact our client service team at bd(at)snbl-cpc(dot)com or visit our website at http://www.snbl-cpc.com.
+1 (410) 706 8894